ACM
ARKG icon

Arlington Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Arlington Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-224,280
Closed -$5.38M – 47
2018
Q4 		$5.38M Buy
+224,280
New +$6.32M 3.99% 10

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CFA
Carroll Financial Associates Charlotte, North Carolina $1.88B AUM 20.52% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
BCM
Barometer Capital Management Toronto, Ontario, Canada $292M AUM 86.78% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return

Arlington Capital Management's ARKG Position: Q1 2019 in Review

Arlington Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2019, closing a stake of 224,280 shares — an estimated $5.38M sold.

Arlington Capital Management first reported a position in ARKG in Q4 2018 and held it in 1 quarter. The position peaked at $5.38M in Q4 2018. 64 funds tracked by Wall St. Rank hold ARKG as of Q1 2019.

  • Arlington Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2019 after selling out during the quarter.
  • Arlington Capital Management sold 224,280 ARK Genomic Revolution ETF shares in Q1 2019, an estimated $5.38M.
  • Arlington Capital Management first reported a position in ARK Genomic Revolution ETF in Q4 2018 and held it in 1 quarter.
  • Arlington Capital Management's ARK Genomic Revolution ETF position peaked at $5.38M in Q4 2018.
  • 64 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2019.

Based on Arlington Capital Management's 13F filing for Q1 2019, filed 10 May 2019.